| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. | Chief R&D Commercial Officer, Director | Class A Common Stock | 668K | $3.69M | $5.52 | Aug 18, 2025 | Direct |
| RECURSION PHARMACEUTICALS, INC. | Chief R&D Commercial Officer, Director | Stock Option (Right to Buy) | 994K | May 15, 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| RXRX | RECURSION PHARMACEUTICALS, INC. | Aug 15, 2025 | 2 | -$224K | 4 | Aug 19, 2025 | Chief R&D Commercial Officer, Director |
| RXRX | RECURSION PHARMACEUTICALS, INC. | May 15, 2025 | 1 | -$16.1K | 4 | May 19, 2025 | Chief R&D Commercial Officer, Director |
| RXRX | RECURSION PHARMACEUTICALS, INC. | Feb 3, 2025 | 4 | -$20K | 4 | Feb 5, 2025 | Chief R&D Commercial Officer, Director |
| RXRX | RECURSION PHARMACEUTICALS, INC. | Aug 1, 2024 | 2 | $0 | 4 | Aug 5, 2024 | Chief R&D Commercial Officer, Director |
| RXRX | RECURSION PHARMACEUTICALS, INC. | Apr 16, 2024 | 0 | $0 | 3 | Apr 25, 2024 | Director |